GB0718167D0 - Cancer marker and therapeutic target - Google Patents

Cancer marker and therapeutic target

Info

Publication number
GB0718167D0
GB0718167D0 GB0718167A GB0718167A GB0718167D0 GB 0718167 D0 GB0718167 D0 GB 0718167D0 GB 0718167 A GB0718167 A GB 0718167A GB 0718167 A GB0718167 A GB 0718167A GB 0718167 D0 GB0718167 D0 GB 0718167D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic target
cancer marker
marker
cancer
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0718167A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0718167(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Priority to GB0718167A priority Critical patent/GB0718167D0/en
Publication of GB0718167D0 publication Critical patent/GB0718167D0/en
Priority to RU2010123921/15A priority patent/RU2529797C2/ru
Priority to AU2008300413A priority patent/AU2008300413B2/en
Priority to EP12182790.1A priority patent/EP2533047B1/en
Priority to PL08806315T priority patent/PL2176664T3/pl
Priority to EP12183760.3A priority patent/EP2535716B1/en
Priority to ES08806315.1T priority patent/ES2443541T3/es
Priority to JP2010525420A priority patent/JP5774309B2/ja
Priority to DK08806315.1T priority patent/DK2176664T3/da
Priority to CA2699702A priority patent/CA2699702C/en
Priority to ES12182790.1T priority patent/ES2588507T3/es
Priority to PL12182790.1T priority patent/PL2533047T3/pl
Priority to EP08806315.1A priority patent/EP2176664B1/en
Priority to PCT/GB2008/003160 priority patent/WO2009037454A2/en
Priority to DK12183760.3T priority patent/DK2535716T3/en
Priority to US12/679,002 priority patent/US9134293B2/en
Priority to DK12182790.1T priority patent/DK2533047T3/en
Priority to PL12183760T priority patent/PL2535716T3/pl
Priority to ES12183760.3T priority patent/ES2612690T3/es
Priority to RU2014128513A priority patent/RU2014128513A/ru
Priority to JP2015131752A priority patent/JP6234967B2/ja
Priority to US14/823,755 priority patent/US10261099B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
GB0718167A 2007-09-18 2007-09-18 Cancer marker and therapeutic target Ceased GB0718167D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
PL12183760T PL2535716T3 (pl) 2007-09-18 2008-09-18 Marker nowotworowy i cel terapeutyczny
ES12183760.3T ES2612690T3 (es) 2007-09-18 2008-09-18 Marcador de cáncer y diana terapéutica
CA2699702A CA2699702C (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
EP08806315.1A EP2176664B1 (en) 2007-09-18 2008-09-18 Ccr4 as cancer marker
EP12182790.1A EP2533047B1 (en) 2007-09-18 2008-09-18 Ccr4 as therapeutic target for cancer
PL08806315T PL2176664T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako marker nowotworowy
EP12183760.3A EP2535716B1 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
ES08806315.1T ES2443541T3 (es) 2007-09-18 2008-09-18 CCR4 como marcador de cáncer
JP2010525420A JP5774309B2 (ja) 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット
DK08806315.1T DK2176664T3 (da) 2007-09-18 2008-09-18 Ccr4 som cancermarkør
RU2010123921/15A RU2529797C2 (ru) 2007-09-18 2008-09-18 Раковый маркер и терапевтическая мишень
ES12182790.1T ES2588507T3 (es) 2007-09-18 2008-09-18 CCR4 como diana terapéutica para cáncer
PL12182790.1T PL2533047T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako cel terapeutyczny dla nowotworu
AU2008300413A AU2008300413B2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
DK12183760.3T DK2535716T3 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
US12/679,002 US9134293B2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
DK12182790.1T DK2533047T3 (en) 2007-09-18 2008-09-18 CCR4 as a therapeutic target for cancer
RU2014128513A RU2014128513A (ru) 2007-09-18 2014-07-14 Раковый маркер и терапевтическая мишень
JP2015131752A JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット
US14/823,755 US10261099B2 (en) 2007-09-18 2015-08-11 Cancer marker and therapeutic target

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target

Publications (1)

Publication Number Publication Date
GB0718167D0 true GB0718167D0 (en) 2007-10-31

Family

ID=38670078

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0718167A Ceased GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target

Country Status (11)

Country Link
US (2) US9134293B2 (cg-RX-API-DMAC10.html)
EP (3) EP2535716B1 (cg-RX-API-DMAC10.html)
JP (2) JP5774309B2 (cg-RX-API-DMAC10.html)
AU (1) AU2008300413B2 (cg-RX-API-DMAC10.html)
CA (1) CA2699702C (cg-RX-API-DMAC10.html)
DK (3) DK2533047T3 (cg-RX-API-DMAC10.html)
ES (3) ES2612690T3 (cg-RX-API-DMAC10.html)
GB (1) GB0718167D0 (cg-RX-API-DMAC10.html)
PL (3) PL2533047T3 (cg-RX-API-DMAC10.html)
RU (2) RU2529797C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009037454A2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011157678A1 (en) * 2010-06-14 2011-12-22 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
JP6259764B2 (ja) * 2011-10-24 2018-01-10 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 炭酸脱水酵素関連マーカーおよびその使用
US8835419B2 (en) 2011-12-01 2014-09-16 Chemocentryx, Inc. Substituted anilines as CCR(4) antagonists
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
SMT202100473T1 (it) * 2013-11-06 2021-09-14 Janssen Biotech Inc Anticorpi anti-ccl17
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
WO2016050904A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
CA2983126A1 (en) * 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
EP3329244B1 (en) 2015-07-30 2022-10-05 Qiagen GmbH Method of preparing a frozen biological sample
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
US20210163607A1 (en) * 2017-05-19 2021-06-03 Nippon Zenyaku Kogyo Co., Ltd. Method for suppressing regulatory t cell infiltration by ccr4 inhibition and method for treating canine neoplastic disease
MX2021002302A (es) 2018-08-29 2021-04-28 Chemocentryx Inc Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control.
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
SI1270595T1 (sl) 2000-03-03 2008-12-31 Kyowa Hakko Kogyo Kk Protitelo proti CCR4 in njegov fragment
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
SK4702003A3 (en) 2000-10-18 2004-01-08 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
MXPA03007681A (es) * 2001-02-28 2004-11-12 Protein Design Labs Inc Receptores para quimiocinas y enfermedades.
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
JP2005509408A (ja) 2001-08-10 2005-04-14 トピジェン・ファルマスーティック・インコーポレーテッド 細胞ウイルス受容体およびその使用方法
CN100430420C (zh) 2001-08-31 2008-11-05 协和发酵工业株式会社 人cdr-移植抗体及其抗体片段
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
AU2004279739A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Composition of antibody capable of specifically binding CCR4
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
PL2135949T3 (pl) 2006-02-14 2013-03-29 Noxxon Pharma Ag Kwasy nukleinowe wiążące MCP-1
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
EP2533047A1 (en) 2012-12-12
DK2533047T3 (en) 2016-08-22
ES2588507T3 (es) 2016-11-03
JP2010539508A (ja) 2010-12-16
ES2443541T3 (es) 2014-02-19
JP5774309B2 (ja) 2015-09-09
DK2535716T3 (en) 2017-02-13
RU2014128513A (ru) 2016-02-10
EP2535716A2 (en) 2012-12-19
US20160223572A1 (en) 2016-08-04
JP2015212703A (ja) 2015-11-26
PL2533047T3 (pl) 2016-11-30
AU2008300413A1 (en) 2009-03-26
RU2529797C2 (ru) 2014-09-27
US10261099B2 (en) 2019-04-16
EP2176664A2 (en) 2010-04-21
EP2535716B1 (en) 2016-11-02
PL2176664T3 (pl) 2014-04-30
RU2010123921A (ru) 2011-12-20
DK2176664T3 (da) 2014-01-20
PL2535716T3 (pl) 2017-06-30
WO2009037454A3 (en) 2009-05-07
WO2009037454A2 (en) 2009-03-26
CA2699702C (en) 2018-03-06
AU2008300413B2 (en) 2014-09-11
US9134293B2 (en) 2015-09-15
US20100278844A1 (en) 2010-11-04
EP2176664B1 (en) 2013-11-06
CA2699702A1 (en) 2009-03-26
EP2535716A3 (en) 2013-03-13
ES2612690T3 (es) 2017-05-18
EP2533047B1 (en) 2016-05-11
JP6234967B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
PL2535716T3 (pl) Marker nowotworowy i cel terapeutyczny
GB2447796B (en) Iodonitrobenzamide formulations for cancer and viral diseases
ZA201004403B (en) Therapeutic cancer treatments
EP2197533A4 (en) ABLATION OF PROSTATE CANCER
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
GB0717101D0 (en) Tumour marker
PL2155248T3 (pl) Celowanie w ABCB5 w terapii nowotworowej
GB0724251D0 (en) Therapeutic compounds and their use
GB0519405D0 (en) Cancer therapy prognosis and target
GB0722680D0 (en) Therapeutic compounds and their use
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
GB0821537D0 (en) Therapeutic target
GB0700645D0 (en) Targets for disease therapy
GB0703654D0 (en) Sterimatic dose marker
GB0707417D0 (en) Cancer markers and uses thereof
GB0722773D0 (en) Cancer markers and uses thereof
GB0705517D0 (en) Therapeutic compounds and their use
GB0706538D0 (en) Cancer therapeutic
GB0701640D0 (en) Cancer target
GB0612259D0 (en) Cancer therapeutic
GB0606702D0 (en) Cancer therapeutic
GB0421918D0 (en) Cancer therapeutic target
GB0612258D0 (en) Transcutaneous cancer therapeutic
GB0606703D0 (en) Transcutaneous cancer therapeutic

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)